Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant Klebsiella pneumoniae by a bacteriophage-polymyxin combination.

التفاصيل البيبلوغرافية
العنوان:	Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant Klebsiella pneumoniae by a bacteriophage-polymyxin combination.
المؤلفون:	Han ML; Biomedicine Discovery Institute, Infection and Immunity Program, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia., Nang SC; Biomedicine Discovery Institute, Infection and Immunity Program, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia., Lin YW; Biomedicine Discovery Institute, Infection and Immunity Program, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia., Zhu Y; Biomedicine Discovery Institute, Infection and Immunity Program, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia., Yu HH; Biomedicine Discovery Institute, Infection and Immunity Program, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia., Wickremasinghe H; Biomedicine Discovery Institute, Infection and Immunity Program, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia., Barlow CK; Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.; Monash Proteomics and Metabolomics Facility, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia., Creek DJ; Monash Proteomics and Metabolomics Facility, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia., Crawford S; Ramaciotti Centre for Cryo Electron Microscopy, Monash University, Australia., Rao G; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA., Dai C; Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, No.2 Yuanmingyuan West Road, Beijing 100193, China., Barr JJ; School of Biological Sciences, Monash University, 25 Rainforest Walk, Clayton, Victoria 3800, Australia., Chan K; Advanced Drug Delivery Group, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia., Turner Schooley R; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA., Velkov T; Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria 3010, Australia., Li J; Biomedicine Discovery Institute, Infection and Immunity Program, Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia.
المصدر:	Computational and structural biotechnology journal [Comput Struct Biotechnol J] 2022 Jan 06; Vol. 20, pp. 485-495. Date of Electronic Publication: 2022 Jan 06 (Print Publication: 2022).
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology Country of Publication: Netherlands NLM ID: 101585369 Publication Model: eCollection Cited Medium: Print ISSN: 2001-0370 (Print) Linking ISSN: 20010370 NLM ISO Abbreviation: Comput Struct Biotechnol J Subsets: PubMed not MEDLINE
أسماء مطبوعة:	Publication: Amsterdam : Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology Original Publication: Gothenburg, Sweden : Research Network of Computational and Structural Biotechnology
مستخلص:	Resistance to the last-line polymyxins is emerging in multidrug-resistant Klebsiella pneumoniae and phage therapy is a promising alternative. However, phage monotherapy often rapidly causes resistance and few studies have examined antibiotic-phage combinations against K. pneumoniae . Here, we investigated the combination of polymyxin B with a novel phage pK8 against an mcr -1-carrying polymyxin-resistant clinical isolate Kp II-503 (polymyxin B MIC, 8 mg/L). The phage genome was sequenced and bacterial metabolomes were analysed at 4 and 24 h following the treatment with polymyxin B (16 mg/L), phage pK8 (10 ² PFU/mL) and their combination. Minimal metabolic changes across 24 h were observed with polymyxin B alone; whereas a significant inhibition of the citrate cycle, pentose phosphate pathway, amino acid and nucleotide metabolism occurred with the phage-polymyxin combination at both 4 and 24 h, but with phage alone only at 4 h. The development of resistance to phage alone was associated with enhanced membrane lipid and decreased amino acid biosynthesis in Kp II-503. Notably, cAMP, cGMP and cCMP were significantly enriched (3.1-6.6 log 2 fold) by phage alone and the combination only at 4 h. This is the first systems pharmacology study to investigate the enhanced bacterial killing by polymyxin-phage combination and provides important mechanistic information on phage killing, resistance and antibiotic-phage combination in K. pneumoniae . Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2022 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.)
References:	ISME J. 2014 May;8(5):1089-100. (PMID: 24304672) Anal Chem. 2006 Feb 1;78(3):779-87. (PMID: 16448051) Mol Cell. 2010 Sep 10;39(5):809-20. (PMID: 20832731) World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):162-173. (PMID: 28828194) Front Microbiol. 2020 Oct 23;11:594868. (PMID: 33193274) Nat Rev Microbiol. 2020 Jan;18(1):21-34. (PMID: 31690825) J Antimicrob Chemother. 2015 Sep;70(9):2589-97. (PMID: 26023209) Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494. (PMID: 29762782) Infect Dis Clin North Am. 2016 Jun;30(2):391-414. (PMID: 27208765) Front Cell Infect Microbiol. 2019 Feb 18;9:22. (PMID: 30834237) J Antimicrob Chemother. 2019 Nov 1;74(11):3190-3198. (PMID: 31365098) Nat Rev Microbiol. 2010 Jun;8(6):401-12. (PMID: 20453875) ACS Infect Dis. 2015 Nov 13;1(11):568-575. (PMID: 27525307) ISME J. 2016 Aug;10(8):1823-35. (PMID: 26882266) Anal Chem. 2011 Apr 1;83(7):2786-93. (PMID: 21401061) Viruses. 2014 Oct 03;6(10):3778-86. (PMID: 25285538) J Antimicrob Chemother. 2008 Dec;62(6):1311-8. (PMID: 18922815) Nat Microbiol. 2019 Oct;4(10):1645-1653. (PMID: 31209305) Br J Pharmacol. 2018 Jan;175(2):181-191. (PMID: 28685814) Nature. 1980 Jul 17;286(5770):218-22. (PMID: 6250048) Antimicrob Agents Chemother. 2015 Oct;59(10):5873-84. (PMID: 26169401) Bacteriophage. 2011 Mar;1(2):111-114. (PMID: 22334867) Clin Microbiol Rev. 2019 Jan 16;32(2):. (PMID: 30651225) FEMS Microbiol Rev. 2013 Jul;37(4):554-71. (PMID: 23043507) J Med Chem. 2010 Mar 11;53(5):1898-916. (PMID: 19874036) J Infect Dis. 2017 Mar 1;215(5):703-712. (PMID: 28007922) J Antimicrob Chemother. 2016 Aug;71(8):2071-4. (PMID: 27068400) PeerJ. 2016 Jul 26;4:e2261. (PMID: 27547567) Future Microbiol. 2013 Jun;8(6):711-24. (PMID: 23701329) Cell Host Microbe. 2019 Feb 13;25(2):219-232. (PMID: 30763536) Antibiotics (Basel). 2019 Oct 11;8(4):. (PMID: 31614449) BMC Microbiol. 2011 Dec 01;11:258. (PMID: 22133164) Sci Rep. 2017 Mar 30;7:45527. (PMID: 28358014) Evol Appl. 2012 Sep;5(6):575-82. (PMID: 23028398) Viruses. 2019 Apr 17;11(4):. (PMID: 30999559) Clin Microbiol Rev. 2020 May 13;33(3):. (PMID: 32404435) mSystems. 2019 Jan 8;4(1):. (PMID: 30637340) Int J Antimicrob Agents. 2014 Jul;44(1):8-15. (PMID: 24794735) Int J Antimicrob Agents. 2007 Nov;30(5):385-9. (PMID: 17716872) J Bacteriol. 2013 Jul;195(13):2971-81. (PMID: 23625841) J Clin Microbiol. 2009 May;47(5):1611-2. (PMID: 19261795) Res Microbiol. 2013 Jan;164(1):55-60. (PMID: 23000091) J Med Microbiol. 2008 Dec;57(Pt 12):1508-1513. (PMID: 19018021) Microbiol Rev. 1981 Dec;45(4):620-42. (PMID: 6276705) PLoS Genet. 2016 Jul 05;12(7):e1006134. (PMID: 27380413) Bioinformatics. 2012 Apr 1;28(7):1048-9. (PMID: 22308147) Antimicrob Agents Chemother. 2014 Aug;58(8):4762-6. (PMID: 24914122) Nat Rev Microbiol. 2010 May;8(5):317-27. (PMID: 20348932) Pharmacol Rev. 2021 Apr;73(2):679-728. (PMID: 33627412) J Antibiot (Tokyo). 2015 Nov;68(11):661-5. (PMID: 25944532) Lancet. 2000 Oct 21;356(9239):1418. (PMID: 11052592) Nat Biotechnol. 2009 Dec;27(12):1135-7. (PMID: 20010596) FEMS Immunol Med Microbiol. 2012 Jul;65(2):395-8. (PMID: 22524448)
معلومات مُعتمدة:	R21 AI156766 United States AI NIAID NIH HHS
فهرسة مساهمة:	Keywords: Bacteriophage; Central carbon metabolism; Klebsiella pneumoniae; Metabolome; Polymyxin resistance
تواريخ الأحداث:	Date Created: 20220124 Latest Revision: 20220716
رمز التحديث:	20231215
مُعرف محوري في PubMed:	PMC8760530
DOI:	10.1016/j.csbj.2021.12.039
PMID:	35070170
قاعدة البيانات:	MEDLINE

View record from ScienceDirect

Full Text Finder

الوصف
تدمد:	2001-0370
DOI:	10.1016/j.csbj.2021.12.039